-
Sell-Side Debates First Solar's Costs, Gross Margins
Wednesday, December 12, 2018 - 1:48pm | 607Read More...First Solar, Inc. (NASDAQ: FSLR) announced initial 2019 guidance after the market close Tuesday. The Analysts Raymond James analyst Pavel Molchanov maintained a Market Perform rating on First Solar. Credit Suisse analyst Michael Weinstein reiterated a Neutral rating and $53 price...
-
Credit Suisse Upgrades SunPower After Solar Tariff Exemption
Wednesday, September 19, 2018 - 8:59am | 407Read More...SunPower Corporation (NASDAQ: SPWR) shares jumped about 15 percent Tuesday after the company announced that certain interdigitated back contract solar cells and modules will be exempted from solar tariffs that were imposed in January. The Analyst Credit Suisse analyst Michael Weinstein upgraded...
-
Credit Suisse Doubles Down On Bearish Stance Before First Solar's Q1 Print: 'Major Catalysts Are Behind Us'
Tuesday, April 24, 2018 - 2:34pm | 396Read More...First Solar, Inc. (NASDAQ: FSLR) shares have gained 10 percent quarter-to-date, and despite expecting in-line first-quarter results, Credit Suisse is bearish on the solar manufacturer. The Analyst Analyst Michael Weinstein reiterated an Underperform on First Solar with a $57 price target...
-
First Solar And Sunrun: A Renewable Energy Pair Trade From Credit Suisse
Monday, February 12, 2018 - 2:30pm | 432Read More...When the stock market becomes unpredictable and volatile like it did last week, traders often turn to pair trades to mitigate risk. One Wall Street analyst sees a pair of solar stocks that could form the basis for a solid 2018 pair trade. The Analyst Credit Suisse analyst Michael Weinstein has an...
-
An Analyst's Black Hills Corp. Outlook Dims On These Twin Risks
Tuesday, January 9, 2018 - 2:17pm | 402Read More...The potential implications of tax legislation and regulatory headwinds on the gas and electric utility Black Hills Corp (NYSE: BKH) led to a downgrade from Credit Suisse on Tuesday. The Analyst Analyst Michael Weinstein downgraded Black Hills from Outperform to Neutral and lowered his...
-
JPMorgan Diagnoses The MedTech Space: Stock Picks And Pans
Tuesday, January 2, 2018 - 3:45pm | 377Read More...The medical technology space for the most part benefited throughout 2017 and heading into 2018 some Wall Street analysts remain bullish. The Analyst JPMorgan's Michael Weinstein. The Thesis 2017 was a positive year for the MedTech space and was able to overcome multiple challenges,...
-
Credit Suisse: NextEra Energy A 'Premier Solar And Wind Play'
Thursday, December 7, 2017 - 3:42pm | 341Read More...NextEra Energy Inc (NYSE: NEE) managed to post better-than-expected third quarter profit Oct. 26, but failed to beat the revenue consensus in the earnings report. The Analyst Credit Suisse's Michael Weinstein initiated coverage of NextEra Energy with an Outperform rating and $173...
-
JPMorgan: Buy The Boston Scientific Dip
Wednesday, November 29, 2017 - 12:16pm | 514Read More...Boston Scientific Corporation (NYSE: BSX) announced Tuesday after the close a delay to earlier timelines that were established for commercialization of the LOTUS Edge Aortic Valve System in Europe and the U.S. The company had previously looked at reintroducing the product in Europe in the first...
-
JPMorgan Downgrades ConforMIS After Its Sales Outlook Dropped $5 Million
Friday, May 13, 2016 - 9:13am | 277Read More...Although ConforMIS Inc (NASDAQ: CFMS) delivered a 1Q top-line beat, the guidance was disappointing. JPMorgan’s Michael Weinstein downgraded the rating for the company from Overweight to Neutral, while reducing the price target from $18 to $8. He cited the reasons as the reduced 2016...
-
JPMorgan Doesn't See A Competing Bid For St. Jude Medical, Downgrades To Neutral
Friday, April 29, 2016 - 10:58am | 268Read More...On April 28, Abbott Laboratories (NYSE: ABT) announced the acquisition of St. Jude Medical, Inc. (NYSE: STJ) for $82.50 per share. JPMorgan’s Michael Weinstein downgraded the rating on St. Jude Medical from Overweight to Neutral, while raising the price target from $66.00 to $82.50. The...
-
J.P. Morgan Thinks Nervo Is About To Take Off, Sees Major Revenues Coming
Monday, December 14, 2015 - 10:25am | 279Read More...Shares of Nevro Corp (NYSE: NVRO) have appreciated 77.14 percent year to date, shooting up almost to their 52 week high on the morning of December 14. J.P. Morgan’s Michael Weinstein has reiterated an Overweight rating on the company, while raising the price target from $67 to $80....
-
JPMorgan Cut Its Johnson & Johnson Forecast Before Earnings, But Why?
Monday, April 6, 2015 - 2:00pm | 304Read More...In a report published Monday, JPMorgan analyst Michael Weinstein discussed Johnson & Johnson (NYSE: JNJ)'s upcoming first quarter report, scheduled for Tuesday, April 14. Weinstein noted that he is expecting a largely in-line quarter on the top line given an improved pharmaceutical...
-
J.P. Morgan: Johnson & Johnson's Drug Segment May Beat Q2 Street Views
Thursday, July 10, 2014 - 3:31pm | 231Read More...Johnson & Johnson's (NYSE: JNJ) pharmaceuticals products may drive second-quarter results to just above Street views when it reports earnings next week, an analyst said Thursday. J.P. Morgan's Michael Weinstein said the segment is growing at an annual rate of 15 percent. But it'...
-
UPDATE: J.P. Morgan Reiterates on Medtronic Following Solid 2Q Results
Wednesday, November 20, 2013 - 10:56am | 133Read More...In a report published Wednesday, J.P. Morgan analyst Michael Weinstein reiterated a Neutral rating on Medtronic (NYSE: MDT), and raised the price target from $59.00 to $63.00. In the report, J.P. Morgan noted, “Medtronic reported solid 2Q results Tuesday, as revenues of $4.194B (+2.4%, +3.3% cc)...
-
UPDATE: J.P. Morgan Downgrades Edwards Lifesciences Corp. as Street Estimates Are Too High
Wednesday, October 30, 2013 - 10:06am | 191Read More...In a report published Wednesday, J.P. Morgan analyst Michael Weinstein downgraded the rating on Edwards Lifesciences Corp. (NYSE: EW) from Neutral to Underweight, and lowered the price target from $64.00 to $62.00. In the report, J.P. Morgan noted, “We're lowering rating on shares of Edwards today...
